We are deeply saddened to learn of the passing of Prof. Marcus Maurer, a highly esteemed expert who contributed significantly to touchDERMATOLOGY. Our hearts and deepest sympathies are with his family and close friends during this difficult time. His guidance, expert insights, and contributions to our platform have been invaluable. We feel privileged to have worked alongside someone whose groundbreaking work has made a significant impact on dermatology and immunology.
Trending Topic
Chronic spontaneous urticaria (CSU), a common and distressing skin condition driven by mast cells, is typically managed with a stepwise approach using second-generation H1-antihistamines, omalizumab and cyclosporine, as recommended by international guidelines. However, many patients with CSU do not respond optimally to this standardized treatment, likely due to the diverse underlying mechanisms involved. As a […]
There are currently multiple therapeutics showing promise in clinical trials for chronic urticaria including anti-IL-4 monoclonal antibodies, Bruton’s tyrosine kinase (BTK) inhibitors and anti-KIT-monoklonal antibodies. touchDERMATOLOGY were delighted to speak with Expert Faculty member Professor Emek Kocatürk (Koç University School of Medicine, Istanbul, Turkey & Charite University Institute of Allergology) to discuss the latest advancements and investigational therapeutics in chronic urticaria medicine. The presentation 'Incoming treatments for Chronic Urticaria' (Presentation ID D2T05.3C) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions Could you give us a brief overview of the current guidelines for chronic urticaria management? (0:30) What investigational therapeutics show promise for chronic urticaria? (3:49) Disclosures: Emek Kocatürk discloses serving on advisory boards for Novartis, and Menarini. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.Â
Ligelizumab is a monoclonal antibody recently investigated in the phase 3 PEARL-1 and PEARL-2 studies for the treatment of chronic spontaneous urticaria (ClinicalTrials.gov Identifiers: NCT03580369 & NCT03580356). In this touchIMMUNOLOGY interview, we spoke with Dr. Luis Felipe C. Ensina (Federal ...
Phase 2 results of remibrutinib for chronic spontaneous urticaria (CSU) show a fast and sustained response to treatment. While the phase 3b trial is ongoing, touchIMMUNOLOGY were delighted to speak with Prof. Marcus Maurer (Professor of Dermatology and Allergy, Charité – Universitä...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Or use a .
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
